IFNs are helicoidal cytokines released by host cells in response to the presence of pathogens or tumor cells. Human IFNs have been classified into three major types on the basis of the cognate receptors through which they signal, gene sequence similarity, and chromosomal location ([@bib59]). Type I IFNs include 17 subtypes (13 subtypes of IFN-α and IFNs β/ε/κ/ω), all of which bind to a receptor composed of two chains, IFNAR1 and IFNAR2 ([@bib77]). The genes encoding type I IFNs are intronless and are located in a region spanning ∼400 kb on chromosome 9, with the exception of *IFNK*, which is located ∼6 Mb away from the other type I IFN genes ([@bib75]; [@bib34]; [@bib21]). There is only one type II IFN, IFN-γ, which signals via a receptor composed of the IFN-γR1 and IFN-γR2 subunits ([@bib82]; [@bib59]). The more recently described type III IFNs constitute a group of three cytokines, IL-28A, IL-28B, and IL-29 (also known as IFN-λ2, IFN-λ3, and IFN-λ1, respectively), the genes for which are clustered in an ∼50-kb region of chromosome 19 ([@bib41]; [@bib68]). These IFNs activate a signaling pathway similar to that of type I IFNs, but act via a different receptor composed of the type III IFN-specific IL-28RA and the IL-10RB, the latter subunit being also used by the IL-10 and IL-22 receptor ([@bib40]; [@bib85]). There is increasing evidence to suggest that type I and III IFNs have a different role from the type II IFN: IFN-α/β and IFN-λ appear to have potent antiviral activities, whereas IFN-γ has antibacterial, antiparisitic, and antifungal properties ([@bib59]; [@bib86]).

In recent years, human genetics studies of both Mendelian and complex diseases have identified several variants affecting the production of, or the response to, IFNs, shedding light on the genuine functions of IFNs in the natural setting ([@bib86]). Disorders or specific mutations in genes involved in the IFN-γ circuit, such as in *IFNGR1* and *IFNGR2*, confer a Mendelian predisposition to mycobacterial disease ([@bib25]), whereas the disorders or specific mutations in patients with impaired type I or type III responses are associated with a stronger predisposition to viral infections ([@bib22]; [@bib13]; [@bib53]). Likewise, mutations affecting type I or type III IFN responses have been associated with various autoimmune pathologies (Crow et al., 2006a,b; [@bib32]; [@bib63]). Several epidemiological genetics studies have recently shown that genetic variants in the region encompassing the type III IFN *IL28B* gene are associated with the spontaneous clearance of hepatitis C virus (HCV) and the response to HCV therapeutic treatment ([@bib29]; [@bib70]; [@bib72]; [@bib73]).

Our understanding of the mechanisms controlling IFN production, the downstream signaling pathways associated with these molecules, and their involvement in physiology and pathology is starting to be fully appreciated, but several biological questions remain unanswered. Given that multiple IFN molecules signal through the same receptor (e.g., IFN-α/β and IFN-λ), are all IFNs equally relevant to host survival? Are some IFN genes more essential for immunity to infection whereas others display immunological redundancy? Does IFN-γ, which is not a prototypic antiviral cytokine, have a distinctive evolutionary signature? Has genetic variation at specific IFN gene loci conferred a selective advantage to the host, associated with an increase in resistance to infectious disease? Here, we tackled these questions using an evolutionary genetics approach, which investigates the way in which infections have shaped the variability of host defense genes by natural selection ([@bib66]; [@bib54]; [@bib5]). This approach, which has been shown to be an indispensable complement to clinical and epidemiological genetics, and to immunological studies ([@bib11]; [@bib61]; [@bib12]), should help to determine the biological relevance of IFNs in the setting of a natural ecosystem governed by natural selection.

RESULTS
=======

Full sequencing of genes encoding the human IFNs and their receptors
--------------------------------------------------------------------

To obtain insight into the selective forces that have driven the evolution of the three families of IFNs in humans, we characterized the levels of sequence-based diversity in the 21 genes encoding the IFNs and the 6 genes encoding their receptor chains by full resequencing in a panel of 186 healthy individuals originating from sub-Saharan Africa, Europe, and Asia. We sequenced a total of 81.5 kb in each individual---24% of which corresponded to protein-coding regions, the rest comprising noncoding exons, introns, and promoter regions ([Table S1](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp1})---and identified 1,066 polymorphisms, including 988 single-nucleotide polymorphisms (SNPs) and 78 insertions/deletions ([Table S2](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp2}). This resequencing dataset was used to estimate several population genetic parameters and summary statistics that were, when relevant, compared with available genome-wide datasets based on genotyping or resequencing. These analyses allowed us to explore the effects of natural selection on IFN evolution since the divergence of the human and chimpanzee lineages and within different human populations.

Naturally occurring genetic diversity varies between IFNs and populations
-------------------------------------------------------------------------

We observed remarkable differences in the levels of nucleotide diversity within the population between the genes encoding the various IFNs and their receptors and between IFN families ([Fig. 1](#fig1){ref-type="fig"} and [Table S3](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp3}). The extremely low level of nucleotide diversity observed for the type II *IFNG*, which was uniform across populations, contrasted with several type I IFNA genes, such as *IFNA4*, *IFNA7*, *IFNA10*, *IFNA16*, *IFNA17*, and *IFNA21*, which displayed high levels of diversity ([Fig. 1 A](#fig1){ref-type="fig"}). In accordance with the "Out of Africa" model ([@bib49]) and genome-wide datasets (i.e., HapMap and 1,000 Genomes Project; [@bib2]; [@bib23]), African populations generally displayed the highest levels of diversity. However, one third of the IFN genes (mostly type I IFNA genes: *IFNA4*, *IFNA5*, *IFNA6*, *IFNA7*, *IFNA14*, and *IFNA17*) were most diverse in the Asian population, which in turn presented the lowest diversity for the three members of the type III IFN family ([Fig. 1](#fig1){ref-type="fig"} and Table S3).

![**Patterns of nucleotide diversity for the three families of IFN genes and for the genes encoding their receptors in human populations.** (A) Nucleotide diversity levels for the individual genes in populations representing major ethnic groups. The expected diversity (dotted lines) corresponds to the mean diversity levels observed for 20 autosomal noncoding regions in each geographic area ([@bib45]). (B) Comparison of nucleotide diversity between IFN families and receptors.](JEM_20111680_Fig1){#fig1}

Because the type I IFNA genes, as well as the three type III IFN genes, display high levels of sequence identity and are organized into two distinct clusters of paralogous genes ([@bib59]; [@bib84]), gene conversion is likely to have been an important mechanism for the evolution of these gene families. Indeed, in multigene families, gene conversion among paralogous loci has been shown to play an important role in the introduction of genetic variation to each gene ([@bib36]; [@bib57], [@bib58]). We thus evaluated the extent to which gene conversion has contributed to the levels of nucleotide diversity observed at these two groups of IFN genes. To do so, we screened highly homologous regions among paralogs for the presence of human-specific sites (polymorphic or fixed) that have been most likely introduced by gene conversion events rather than by point mutations (Materials and methods). This analysis allowed us to detect a substantial number of putative gene conversion events ([Table S4](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp4}), 30 of which corresponded to polymorphic amino acid--altering mutations ([Table S5](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp5}). As gene conversion is usually disregarded in population genetics tests, owing to the uncertainty associated with the underlying models of gene conversion, all variants identified as resulting from gene conversion were not considered in the statistical analyses to detect natural selection.

Functional diversity is not evenly distributed between human IFNs
-----------------------------------------------------------------

We identified 245 SNPs in coding regions, including 164 nonsynonymous and 8 nonsense mutations present in the general human population. The occurrence and frequency distribution of these variants differed markedly between the various IFNs and between populations ([Fig. 2](#fig2){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}, and Table S3). IFNs with very low levels of amino acid--altering variation are represented by *IFNG*, in which no nonsynonymous mutations were observed, and by a group of type I IFNs (*IFNA2*, *IFNA5*, *IFNA6*, *IFNA8*, *IFNA13*, *IFNA14*, *IFNA21*, *IFNB1*, *IFNK*, and *IFNW1*) and the two receptor subunits *IFNGR1* and *IL28RA*, which presented nonsynonymous mutations at a low frequency within the population. In contrast, we found that 13 genes accumulated nonsynonymous variants at very high frequency in the human population (∼30--100%; [Fig. 2](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Most of these variants were predicted to be benign by the PolyPhen algorithm ([@bib1]), but some genes, such as *IFNA10*, *IFNA16*, *IFNA17*, *IFNAR1*, *IL28A*, and *IL29*, presented high frequencies of missense mutations predicted to alter protein function (i.e., damaging mutations; [Table 1](#tbl1){ref-type="table"} and Table S3). The most extreme cases were those of *IFNA10* and *IFNE*, for which nonsense mutations were present in the homozygous state, at high frequency, in several populations. For example, one of the nonsense mutations of *IFNA10* (SNP 60T\>A, C20STOP, rs10119910), which is located in the signal peptide, abolishes the translation of the entire protein. Surprisingly, this stop mutation has attained a worldwide frequency of 34%, ranging from 18% in Europeans to 54% in Asians. The *IFNE* nonsense mutation (SNP 211C\>T, Q71STOP, rs2039381) decreases the length of the protein by two thirds and has attained a worldwide frequency of 7%, increasing to 15% in Asia. Such high frequencies of nonsynonymous or nonsense mutations in some IFN genes may reflect either a relaxation of selective constraints caused by the redundancy of the genes concerned, or a selective advantage accounted for by the higher frequency of functionally advantageous variants.

![**Proportion of chromosomes carrying at least one nonsynonymous or nonsense variant in the general human population.** The red portion of the pie charts corresponds to the proportion of chromosomes carrying at least one nonsynonymous polymorphism, the black portion to the proportion of chromosomes carrying at least one nonsense polymorphism, and the blue portion to the proportion of chromosomes carrying neither nonsynonymous nor nonsense polymorphisms. Genes shaded in gray correspond to those encoding the receptor subunits of each IFN family.](JEM_20111680_Fig2){#fig2}

###### 

Coding variation at IFN genes and their receptors in human populations

                               Number of polymorphisms[a](#tblfn1){ref-type="table-fn"}   Highest derived allele frequency[b](#tblfn2){ref-type="table-fn"}   Proportion of chromosomes[c](#tblfn3){ref-type="table-fn"}                                            
  -------------- ------ ------ ---------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------ ------- ------- ------- -------- ------- -------
  ***IFNA1***    1835   440    5                                                          1                                                                   0                                                            94.62   0.27    0       97.85    0.27    0
  ***IFNA2***    2030   438    3                                                          0                                                                   0                                                            1.08    0       0       2.69     0       0
  ***IFNA4***    1839   439    10                                                         1                                                                   0                                                            99.73   0.27    0       100.00   0.27    0
  ***IFNA5***    1300   443    4                                                          3                                                                   1                                                            0.54    0.54    0.27    2.96     1.08    0.27
  ***IFNA6***    1464   441    3                                                          1                                                                   0                                                            0.54    0.27    0       0.81     0.27    0
  ***IFNA7***    1285   441    5                                                          0                                                                   0                                                            99.46   0       0       99.46    0       0
  ***IFNA8***    1889   440    1                                                          0                                                                   0                                                            7.26    0       0       7.26     0       0
  ***IFNA10***   1644   438    13                                                         0                                                                   3                                                            98.12   0       34.14   100.00   0       34.68
  ***IFNA13***   1461   440    3                                                          0                                                                   0                                                            5.11    0       0       6.99     0       0
  ***IFNA14***   1216   448    2                                                          0                                                                   1                                                            0.54    0       0.27    0.81     0       0
  ***IFNA16***   1700   439    7                                                          1                                                                   0                                                            97.58   97.04   0       100.00   97.04   0
  ***IFNA17***   1710   438    6                                                          1                                                                   0                                                            65.86   65.86   0       98.39    65.86   0
  ***IFNA21***   1801   440    9                                                          1                                                                   1                                                            4.03    0.27    0.27    8.87     0.27    0.27
  ***IFNB1***    1520   439    5                                                          1                                                                   0                                                            1.61    0.27    0       3.23     0.27    0
  ***IFNE***     2156   490    3                                                          1                                                                   1                                                            2.15    0.27    7.26    3.49     0.27    7.26
  ***IFNK***     2186   496    4                                                          3                                                                   0                                                            6.99    2.69    0       10.75    3.76    0
  ***IFNW1***    2151   451    6                                                          5                                                                   0                                                            4.30    4.30    0       5.91     5.65    0
  ***IFNAR1***   5250   1303   9                                                          1                                                                   0                                                            20.43   0.27    0       29.30    0.27    0
  ***IFNAR2***   5737   1201   10                                                         5                                                                   0                                                            58.87   0.81    0       74.19    2.42    0
  ***IFNG***     4172   395    0                                                          0                                                                   0                                                            0       0       0       0        0       0
  ***IFNGR1***   4345   1130   10                                                         2                                                                   0                                                            1.87    0.27    0       5.65     0.54    0
  ***IFNGR2***   4015   715    6                                                          1                                                                   0                                                            76.33   0.27    0       77.15    0.27    0
  ***IL28A***    1325   303    8                                                          1                                                                   1                                                            92.74   80.11   0.27    100.00   80.11   0.27
  ***IL28B***    3031   434    12                                                         3                                                                   0                                                            62.63   3.49    0       65.59    3.76    0
  ***IL29***     1558   443    5                                                          1                                                                   0                                                            70.16   70.16   0       73.12    70.16   0
  ***IL28RA***   3295   1177   10                                                         4                                                                   0                                                            3.76    3.76    0       11.29    4.84    0
  ***IL10RB***   3696   721    5                                                          1                                                                   0                                                            32.53   0.54    0       34.41    0.54    0

Absolute numbers of polymorphisms observed in our entire dataset

Among the different variants observed in each category, the value (in %) of the most frequent polymorphism is shown

Proportion of chromosomes (in %) in the general population carrying at least one nonsynonymous or nonsense variant. NS stands for nonsynonymous. "PRD" refers to "probably damaging" mutations as predicted by PolyPhen v2 HumDiv.

Purifying selection has operated differently among IFN family members
---------------------------------------------------------------------

We investigated whether and how natural selection has driven the observed heterogeneous patterns of diversity of the various IFNs and their receptors by first estimating the direction and strength of selection within the human species as a whole. To this end, we measured *d~S~* and *d~N~*, i.e., the number of silent and nonsynonymous fixed differences between humans and chimpanzees, together with *p~S~* and *p~N~*, i.e., the number of silent and nonsynonymous polymorphic sites observed within humans. We used the McDonald-Kreitman Poisson random field method ([@bib67]; [@bib9]) to estimate ω (i.e., ω α θ~N~/θ~S~, where θ~N~ and θ~S~ are estimates of the rate of nonsynonymous and silent mutations) and to assess the selection pressure driving amino acid substitutions. Under neutrality, ω is not significantly different from 1. Values \<1 indicate a deficit of nonsynonymous variants, whereas values \>1 reflect an excess of amino acid changes. We found that only *IFNA6*, *IFNA8*, *IFNA13* and *IFNA14*, and *IFNG* had ω values significantly \<1, consistent with their evolution under the strongest purifying selection ([Fig. 3](#fig3){ref-type="fig"}). Among type I IFNs, we removed from our analyses a few low-frequency nonsynonymous mutations that were found to result from gene conversion at *IFNA6*, *IFNA13*, and *IFNA14*, whereas no gene conversion events were detected at *IFNA8* (Table S5). Our simulation analyses showed that the removal of gene conversion--derived events cannot produce spurious signals of purifying selection ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp6}). However, because of the minimal, but nonnull, uncertainty in our procedure for gene conversion detection, *IFNA8* represents the most robust target of purifying selection among type I IFNs. At the other extreme, *IL28B* was the only gene that had a ω value significantly greater than 1, consistent with the action of positive selection.

![**Estimation of the intensity of natural selection acting on the various IFN families and their receptors.** The strength of natural selection was assessed by estimating ω values. Under neutrality, ω is not significantly different from 1. Values below 1 are consistent with selection against nonsynonymous variants, whereas values greater than 1 indicate an excess of amino acid changes. Bars indicate 95% Bayesian confidence intervals, and red circles indicate genes with ω estimates significantly above or below 1. Genes shaded in gray correspond to those encoding the receptor subunits of each IFN family.](JEM_20111680_Fig3){#fig3}

Positive selection has targeted type III IFNs in non-African populations
------------------------------------------------------------------------

We next investigated the ways in which positive selection has affected IFN genes in a population-specific manner, as populations from different continents have clearly been historically exposed to different selection pressures ([@bib55]). We performed various intraspecies neutrality tests on various aspects of the data, including the allele frequency spectrum (i.e., Tajima's *D*, Fu and Li's *D*\* and *F*\*, and Fay and Wu's *H* tests), levels of population differentiation (i.e., *F*~ST~), and haplotype-based tests (i.e., derived intrallelic nucleotide diversity \[DIND\] and integrated haplotype score \[iHS\] tests; [@bib43]; [@bib54]). As most of these tests are known to be sensitive to the effects of demography and selection, we used simulation-based or empirical procedures to correct for the influence of demography on the patterns of population genetic diversity. For the allele frequency spectrum and DIND tests, we incorporated into our neutral expectations two demographic models based on multiple, noncoding genomic regions sequenced in a set of populations similar to those used in this study ([@bib80]; [@bib45]). For the population differentiation tests, we obtained a background expectation of genome-wide *F*~ST~ by analyzing the publicly available HGDP-CEPH dataset ([@bib50]) from the same set of individuals we sequenced in this study. In addition, we complemented our analyses of recent positive selection by obtaining the iHS values for each SNP in the populations of the HapMap Phase II dataset ([@bib28]).

We defined genes under selection conservatively as those (a) for which significant results were obtained after both demographic corrections or for which results were significant at the genome-wide level, and (b) for which significant results were obtained in at least two tests of selection based on different aspects of the data (e.g., allele frequency spectrum tests and *F*~ST~) in the same population. With these stringent criteria, most type I IFNs and the type II IFN did not show compelling signatures of selection in any of the continental populations here studied. In contrast, we found that positive selection had strongly affected the members of the type III IFN family in European and Asian populations ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, and [Table 2](#tbl2){ref-type="table"}). In addition, the results of the neutrality tests for type III IFNs remained significant after correction for multiple testing, emphasizing the intensity of the events of positive selection detected. The three type III IFN genes are adjacent to each other on an ∼50-kb region of chromosome 19 ([Fig. 6](#fig6){ref-type="fig"}), but they nonetheless displayed low levels of linkage disequilibrium in all populations ([Fig. S2](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp7}). This suggests that independent positive selection events have targeted *IL28A*, *IL28B*, and *IL29*.

![**Detection of positive selection in Asia using the DIND test.** We plotted iπ~A~/iπ~D~ values against derived allele frequencies (DAFs). P-values were obtained by comparing the iπ~A~/iπ~D~ values for the three type III IFN genes against the expected iπ~A~/iπ~D~ values obtained in 10^4^ simulations, taking into account the most conservative demographic model ([@bib45]). The top dashed line on the graph corresponds to the 99th percentile, and the bottom to the 95th percentile. Dots above the 95th percentile dashed line correspond to mutations that have increased in frequency faster than expected under neutrality in the Asian population. These mutations have been most likely targeted by positive selection, and thus conferred an advantage to the host. Red and black dots correspond to nonsynonymous and silent polymorphisms, respectively. For DIND analyses concerning all genes encoding the 27 IFNs and their receptors in all populations, see [Fig. S3](http://www.jem.org/cgi/content/full/jem.20111680/DC1){#supp8}.](JEM_20111680_Fig4){#fig4}

![**Detection of positive selection on the basis of levels of population differentiation.** Population pairwise *F*~ST~ values are plotted against expected heterozygosity for all the SNPs identified in our study for Africans versus Europeans (A), Africans versus Asians (B), and Europeans versus Asians (C). The dashed lines represent the 99th and 95th percentiles of the HGDP-CEPH genotyping dataset for the same individuals (represented by the density area in blue; [@bib50]). Black dots correspond to silent polymorphisms and red dots correspond to nonsynonymous polymorphisms.](JEM_20111680_Fig5){#fig5}

![**Spatial distribution of positively selected variants across type III IFN genes.** Genomic organization of the three members of the type III IFN family, *IL28B*, *IL28A*, and *IL29*. Filled boxes correspond to exonic regions, and arrows above exons indicate the direction of the open reading frame. Genetic variants displaying signatures of population-specific positive selection are shown; noncoding SNPs are indicated in black and amino acid changes in red. At the gene level, *IL28A* and *IL28B* displayed signatures of positive selection in Asia, and *IL29* in both Europe and Asia ([Table 2](#tbl2){ref-type="table"}). At the SNP level, the action of positive selection targeting the five SNPs at *IL28B* and the two at *IL28A* was supported by the DIND test ([Fig. 4](#fig4){ref-type="fig"}), whereas that at the *IL29* D188N variant was supported by the DIND test and iHS, as well as by the levels of population differentiation ([Fig. 5](#fig5){ref-type="fig"}).](JEM_20111680_Fig6){#fig6}

###### 

Sequence-based neutrality tests across the 27 genes encoding the IFNs and their receptors

                  AFRICA   EUROPE        ASIA                                                                                                                          
  --------------- -------- ------------- ----------- --------- ------------ --------------- --------------- -------------- ------------- -------------- -------------- ---------
  TYPE I IFNs                                                                                                                                                          
  *IFNA1*         −0.15    0.09          0.00        −1.06     −1.59^†^     −0.82           −1.31           −3.20\*        −0.97         −0.65          −0.91          −3.07\*
  *IFNA2*         −1.42    −0.01         −0.64       −0.94     −0.02        0.41            0.31            0.90           0.54          0.12           0.31           0.20
  *IFNA4*         −0.88    −1.57         −1.56       −0.69     0.28         −0.97           −0.61           −2.59\*        1.24          −0.68          0.04           0.43
  *IFNA5*         −0.93    −0.65         −0.89       0.06      −1.09        −2.42^†^        −2.33^\*†^      −0.66          0.19          −0.42          −0.25          0.40
  *IFNA6*         −0.92    0.28          −0.16       0.60      −0.22        −0.31           −0.33           0.67           0.31          −0.07          0.07           0.45
  *IFNA7*         −1.78    −1.55         −1.94       −0.96     −1.32        −1.55           −1.74           0.27           −0.58         0.12           −0.14          −1.14
  *IFNA8*         −0.47    −0.11         −0.29       0.72      −0.72        −2.21^†^        −1.99           0.47           −0.33         −0.49          −0.52          0.85
  *IFNA10*        −0.39    1.11          0.62        −1.81\*   −1.20        −0.59           −0.98           −1.95          0.86          −1.59          −0.83          −0.41
  *IFNA13*        0.10     1.36^\*†^     1.09^\*†^   0.35      −0.63        −0.65           −0.77           −1.00          −0.17         −3.01^\*†^     −2.38^\*†^     0.09
  *IFNA14*        −1.70    −1.80         −2.10       −0.66     −1.37        −2.83^\*†^      −2.77^\*†^      −0.94          0.68          −0.31          0.01           0.28
  *IFNA16*        −1.14    0.33          −0.31       −3.40\*   −0.96        1.28            0.51            −4.75^\*\*†^   0.67          0.27           0.49           −0.06
  *IFNA17*        0.21     0.68^\*†^     0.60^†^     −0.64     −0.06        −0.68           −0.53           −1.50          1.51          −0.82          0.07           0.27
  *IFNA21*        −1.12    −2.37         −2.28       0.16      0.62         0.28            0.47            0.42           0.51          0.41           0.53           −0.30
  *IFNB1*         −1.38    −1.06         −1.41       -0.79     −0.28        −1.25           −1.09           −1.00          −0.08         −0.42          −0.36          −0.65
  *IFNE*          −0.51    −0.35         −0.49       0.69      −0.29        −0.42           −0.45           −0.03          0.19          −1.02          −0.71          0.08
  *IFNK*          −0.89    −0.65         −0.89       0.08      −0.90        −1.52           −1.54           −0.53          −0.84         −3.25^\*†^     −2.81^\*†^     −0.99
  *IFNW1*         −1.07    −1.14         −1.33       0.61      −1.36        −3.45^\*\*†^    −3.20\*\*       0.36           −0.33         −0.82          −0.77          0.76
  *IFNAR1*        −0.82    −0.77         −0.95       -0.27     0.46         −0.43           −0.11           1.10           −0.05         −3.50^\*\*†^   −2.66^\*†^     0.75
  *IFNAR2*        −0.99    −2.58         −2.31       -0.71     1.03         −0.39           0.19            −0.10          −0.01         −1.76          −1.28          −0.94
  TYPE II IFN                                                                                                                                                          
  *IFNG*          −1.60    −1.39         −1.76       -2.10\*   0.34         −1.02           −0.65           −0.42          0.70          0.12           0.37           −0.11
  *IFNGR1*        −1.44    −2.13         −2.23       -0.26     0.27         −2.02           −1.43           0.44           −0.37         −0.95          -0.88          0.55
  *IFNGR2*        −1.13    −3.09         −2.77       -0.37     0.39         −1.63           −1.05           −0.54          −0.73         −4.08^\*\*†^   −3.36^\*\*†^   −0.92
  TYPE III IFNs                                                                                                                                                        
  *IL28A*         −0.95    −1.99         −1.90       -2.50     −0.93        −1.33           −1.42           −0.05          −1.92^\*††^   −3.39^\*\*†^   −3.42^\*\*†^   −0.89
  *IL28B*         −0.18    1.18^\*\*†^   0.75^†^     0.42      0.66         −1.06           −0.48           −1.73          −1.57^\*†^    −3.01^\*†^     −2.94^\*†^     −2.35\*
  *IL29*          −1.00    −2.00         −1.95       -0.33     −1.72^\*†^   −3.81^\*\*††^   −3.68^\*\*††^   −1.41          −1.71^\*††^   −0.86          −1.36          −1.56
  *IL28RA*        −0.64    −0.93         −0.97       -0.24     −0.20        −1.52           −1.22           −0.28          -0.83         −2.63^\*†^     −2.33^\*†^     −0.19
  *IL10RB*        −0.32    −0.63         −0.60       −0.66     1.50         −0.55           0.26            0.28           0.53          −1.32          −0.74          −0.35

TD, Tajima's *D*; D, Fu & Li's *D*\*; F, Fu & Li's *F*\*; Hn, normalized Fay && Wu's *H*. \*\*/\*, P ≤ 0.01 and ≤ 0.05, respectively, according to the model of ([@bib80]); ††/†, P ≤ 0.01 and ≤ 0.05, respectively, according to the model of ([@bib45]).

*IL28A* and *IL28B* deviated significantly from neutral expectations in the Asian population, in allele frequency spectrum tests ([Table 2](#tbl2){ref-type="table"}). Furthermore, the derived alleles of two SNPs in *IL28A* and five in *IL28B* were found to be associated with significantly lower levels of surrounding nucleotide diversity, given their high population frequency (\>90%), in Asia (see the DIND test in [Fig. 4](#fig4){ref-type="fig"}). Interestingly, the two SNPs in *IL28A* and one in *IL28B* correspond to amino acid--altering variants (*IL28A* SNP 983G\>A, A112T, rs8103362; *IL28A* SNP 1227C\>T, H160Y, rs61735713; *IL28B* SNP 502G\>A, R70K, rs8103142). These amino acid changes therefore appear to have increased in frequency more rapidly than would be expected under neutrality, in the Asian population, consistent with the action of population-specific positive selection.

We also detected strong signals of positive selection at the *IL29* locus. First, allele frequency spectrum tests detected a significant excess of rare variants in both Europeans and Asians ([Table 2](#tbl2){ref-type="table"}). Second, very high levels of population differentiation were observed at the *IL29* locus between African and Eurasian populations (mean *F*~ST~ = 0.42). In particular, the nonsynonymous variant 2054G\>A (D188N, rs30461, predicted to be probably damaging by PolyPhen), presented extreme levels of differentiation between Africans and Eurasians (*F*~ST~ Africa/Asia = 0.71, P = 0.014; *F*~ST~ Africa/Europe = 0.66, P = 0.025, using the HGDP-CEPH dataset; [Fig. 5](#fig5){ref-type="fig"}). Remarkably, this SNP not only presented the highest degree of population differentiation of all SNPs in our dataset but was also among the most highly differentiated SNPs at the level of the entire human genome. Indeed, the D188N variant falls into the group of 139 nonsynonymous SNPs presenting the largest allele frequency differences among populations in the 1,000 Genomes project ([@bib23]). In addition, this nonsynonymous variant gave a significant result for the DIND test in Asian populations (iπ~A~/iπ~D~ = 3.71, P \< 0.01; [Fig. 4](#fig4){ref-type="fig"}) and gave a significant iHS value of -2.285 in Europeans from the HapMap Phase II dataset (iHS was not calculated for Asian HapMap populations, because this SNP has a frequency \>95%). These results suggest that *IL29* variation, and the D188N variant in particular, has conferred a selective advantage to Eurasian populations.

DISCUSSION
==========

In this study, we demonstrate that the different IFN families, and their individual members, have followed different evolutionary trajectories in humans. First, we found that type I IFN subtypes differ in their levels of evolutionary constraint. Amino acid--altering variation has been constrained for some type I IFNs, with *IFNA6*, *IFNA8*,*IFNA13*, and *IFNA14* found to have been subject to the strongest purifying selection ([Fig. 3](#fig3){ref-type="fig"}). Low levels of amino acid--altering variation were also observed at *IFNA2*, *IFNA5*,*IFNA21*, *IFNB1*, *IFNK*, and *IFNW1* ([Fig. 2](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Conversely, selective constraints have been relaxed for other type I IFNs, which harbor nonsynonymous variants at high population frequencies (*IFNA1*, *IFNA4*, *IFNA7*, *IFNA10*, *IFNA16*, and *IFNA17*). Furthermore, some IFNs present nonsense mutations in the homozygous state (*IFNA10* and *IFNE*), suggesting that they might be currently undergoing pseudogenization. We also found that some nonsynonymous polymorphisms at several IFNA genes, for the most part observed at low population frequencies, appear to have been introduced by gene conversion from their paralogs (Table S5). This observation supports the notion that, besides gene duplication, gene conversion has contributed to the evolution of type I IFNs in mammals ([@bib35]; [@bib84]; [@bib31]). Together, the strong constraints characterizing some type I IFNs suggest that they fulfill an essential, nonredundant function in host defense. In contrast, the high population frequencies of missense or nonsense mutations, occurring through mutation or gene conversion, found in other type I IFN subtypes, suggest that these molecules are highly redundant.

Our findings provide evolutionary evidence of the complexity of the biological actions of type I IFNs. Indeed, in the mouse model, they play a key role in protective antiviral immunity to multiple experimental infections ([@bib38]; [@bib79]). In humans, primary immunodeficiencies of the type I IFN pathway, including STAT-1 and TYK-2 deficiencies, have also shown that type I IFNs are critical for antiviral immunity ([@bib22]; [@bib13], [@bib14]; [@bib53]; [@bib86]). The integration of our population genetics data into a clinical framework thus indicates that at least one subgroup of type I IFNs plays a critical, nonredundant role in antiviral immunity in natural conditions. A greater tolerance for the increase in frequency of missense or nonsense mutations in the general population is observed in another set of type I IFNs, suggesting that the functions they fulfill are largely overlapping with other IFN subtypes. The existence of multiple type I IFNs and differences in their degrees of diversity and redundancy may attest to the great capacity of this host defense system to evolve, to develop efficient antiviral responses.

However, there is a growing body of work showing that type I IFN activity can also be detrimental to the host ([@bib20]; [@bib79]; [@bib76]). Experimental data from mice and clinical observations in human patients have shown that IFN production can be harmful in the context of infection and can increase morbidity ([@bib33]; [@bib64]; [@bib78]). Such adverse effects of increased IFN production, such as systemic lupus erythematosus ([@bib4]; [@bib16]; [@bib47]; [@bib48]), have also been observed in the context of autoimmune diseases ([@bib17]; [@bib3]). In addition, there is increasing evidence to suggest that type I IFNs have opposing roles in viral and bacterial infection ([@bib20]; [@bib79]; [@bib76]). Such a multifaceted mechanism of host defense is illustrated by IFN-α8 and IFN-α13, which are both under strong selective constraint yet display high and low antiviral potency, respectively ([@bib27]; [@bib26]; [@bib42]; [@bib37]; [@bib46]). However, differences in bioactivity between IFN subtypes will depend not only on their respective potencies and distinct receptor-binding chemistries, as recently shown for a subset of type I IFNs ([@bib74]), but also on their individual production. Few studies have systematically assessed the levels of expression of the multiple type I IFNs ([@bib15]; [@bib30]) and, because of the differences in experimental conditions used, there is as yet no clear consensus as to which subtypes are the most expressed in different cell types. In light of this, we hypothesize that type I IFNs presenting various antiviral potencies and/or production could have been maintained, and selected for, to regulate global type I IFN activity. To test this hypothesis, further analyses are needed to (a) characterize the expression and potency of the individual type I IFN subtypes under different conditions of infection and in different cell types, in particular for those exhibiting the strongest signatures of purifying selection; (b) define how the variation in both production and potency of the various subtypes is under genetic control (i.e., host genetic variation in both protein-coding regions and regulatory regions); and (c) evaluate how the combination of the whole set of type I IFN subtypes, with their varying functional diversity, affects downstream transcriptional programs and host responses at the organism level.

Second, we found that the type II *IFNG* was the only gene, across all three families of human IFNs and their receptors, to display a complete absence of amino acid--altering mutations. This gene was subject to the strongest purifying selection of all IFNs, and we previously showed that *IFNG* is among the ∼10% of immune-related genes subject to the most intense selective constraints on amino acid variation in humans ([@bib51]). Clinical genetic studies have demonstrated that six genes involved in the IFN-γ circuit (IL-12/23--IFN-γ) play a critical role in protective immunity ([@bib25]). Specifically, disorders of IFN-γ production caused by mutations affecting IL-12B, IL-12RB1, or specific *NEMO* mutations, and impaired IFN-γ responses caused by *IFNGR1*,*IFNGR2*, or specific *STAT1* mutations, are associated with Mendelian susceptibility to mycobacterial disease in patients resistant to most viruses ([@bib86]). Population and clinical data show that no variation with a significant impact on protein function is tolerated at loci involved in IFN-γ--mediated immunity, indicating that the IFN-γ pathway is essential and nonredundant in host survival, including host defense against mycobacteria.

Finally, our data showed that type III IFNs are the only group of IFNs where selective pressures have involved processes of geographically restricted adaptation, revealing that genetic variation at these genes has conferred a selective advantage to specific human populations ([Fig. 6](#fig6){ref-type="fig"}). There is increasing evidence from clinical genetic studies to support a major role of these molecules in antiviral immunity ([@bib86]), so the selection pressure acting on type III IFN genes may be of viral origin. Strong support for this notion has been provided by recent genome-wide association studies. Indeed, the five *IL28B* polymorphisms we identified as being under positive selection in Asia have been associated with the spontaneous clearance of HCV and a better response to pegylated IFNα-ribavirin treatment for chronic HCV infection in populations of African, European, and Asian ancestry ([@bib29]; [@bib70]; [@bib72]; [@bib73]; [@bib62]). These SNPs include two located in the regulatory region of *IL28B* (SNP -3180A\>G, rs12979860; and SNP -37C\>G, rs28416813), one in an intron (SNP 685C\>T rs11881222), one in the 3′ region (SNP 1388T\>G, rs4803217), and one nonsynonymous SNP of *IL28B* (SNP 502G\>A, R70K, rs8103142). Interestingly, based on the odds ratios for protective alleles, it has been suggested that variation of the *IL28B* gene may confer a stronger protective effect in Asians than in individuals of European or African ancestry ([@bib56]). However, the environmental, genetic, and evolutionary factors underlying this difference remain unknown.

Our data provide new insight into the relationship between type III IFN variation and ethnic background by showing that Asian populations have evolved the most adaptively and protective alleles have increased in frequency among Asians as a result of positive selection, rather than simple genetic drift. Given the chronic and insidious nature of HCV pathogenesis, it is unlikely that HCV, at least in its modern form, is really responsible for the selection pressure exerted on *IL28B*. In light of this, we hypothesize that other ancestral and more virulent flaviviruses are responsible for the selective footprints observed. To this end, it will be instructive to determine whether *IL28B* polymorphisms are associated with natural immunity to related viruses (e.g., hemorrhagic flaviviruses and/or encephalogenic alphaviruses).

The overlap between the *IL28B* variants found here to be under positive selection and those associated with the spontaneous clearance of HCV infection provides an important proof-of-concept for the value of the evolutionary approach, as a complement to epidemiological and medical genetics studies. This is particularly important for positively selected *IL28A* and *IL29* variants, whose function is not yet fully appreciated. The strongest signature of positive selection we observed concerned a nonsynonymous SNP in *IL29* (SNP 2054G\>A, D188N, rs30461) in European and Asian populations. However, the way in which this variant confers a selective advantage to the host and the pathogens responsible for exerting a selective pressure on *IL29* remains to be identified. Because the three type III IFNs operate as independent genetic entities, we propose that the signatures of positive selection, which appear to be independent, displayed by each type III IFN reflect their different relative contributions to human fitness and survival. Additional studies are required to unravel the immunological role and phenotypic expression of type III IFN subtypes, particularly polymorphisms shown to be under positive selection, in relation to susceptibility to, or the pathogenesis of infectious diseases or autoimmune disorders.

In conclusion, our population genetics data indicate that the various members of the human IFN families differ in biological relevance, ranging from highly constrained to redundant and expendable. The identification of individual IFN genes subject to strong constraints or to adaptive evolution, attesting to their important role in immunity to infection, paves the way for additional studies to evaluate the potential of these molecules for use in vaccination, diagnosis, and treatment. More generally, our study provides a paradigm of the use of population genetics in the context of infection, with a view to improving our understanding of the biological importance of immunity-related genes in host defense in the natural setting.

MATERIALS AND METHODS
=====================

### Population samples.

Sequence variation for all human IFNs and their receptors was determined in 186 individuals from sub-Saharan Africa, Europe, and Asia (62 individuals per geographic region) from the HGDP-CEPH panel ([@bib10]). Sub-Saharan African populations were composed of 19 Bantu from Kenya, 21 Mandenka from Senegal, and 22 Yoruba from Nigeria; European populations were composed of 20 French, 14 Italians, 6 Orcadians, and 22 Russians; the Asian populations were composed of 15 Han Chinese and 33 individuals from Chinese minorities, 10 Japanese, and 4 Cambodians. Population structure within continental regions has been shown to be limited ([@bib50]) and to have a negligible influence on the inference of natural selection ([@bib51]). This study was approved by the Institut Pasteur Institutional Review Board (no. RBM 2008.06).

### DNA sequencing.

We sequenced the 27 genes encoding the IFNs and their receptors using Sanger sequencing. Given the extremely high sequence identity among IFN genes (i.e., the type I IFNA genes and type III IFN genes, are organized into two distinct clusters of paralogous genes), Sanger sequencing was the most appropriate choice to differentiate with confidence regions that are highly paralogous. Another advantage of Sanger sequencing is the reliable detection of low-frequency variants, which are the substrate used to detect and estimate the intensity of purifying selection. This contrasts with publicly available whole genome sequence datasets that, even if they include IFNs (e.g., 1,000 Genomes), are depleted for low-frequency variants, particularly nonsynonymous mutations ([@bib23]), because of the low coverage at which the genomes have been sequenced. For each gene, we sequenced all the exon regions and at least as much of the nonexon regions, including intron, 5′, and 3′ regions (Table S1). All sequences were obtained with the Big Dye Terminator kit and a 3730 XL automated sequencer from Applied Biosystems. Sequence files and chromatograms were inspected with GENALYS software ([@bib71]). All singletons or ambiguous polymorphisms were systematically reamplified and resequenced. We were unable to resequence the first exon of *IFNGR2* and the first exon of *IL10RB* for technical reasons, probably because of the very high GC content of the region (73 and 72%, respectively). The reference sequences used are given in Table S1.

### Gene conversion analyses.

Because interlocus gene conversion requires high levels of sequence identity between loci ([@bib52]), we sought to detect gene conversion events based on (a) the local homology observed between two paralogs and (b) the ancestral/derived state of each base pair in humans determined using the corresponding chimpanzee orthologue. For a pair of genes, X and Y, resequenced in two different individuals, each sequence was subdivided in fragments of 40 bp. Each fragment defined in gene X was compared with all the possible fragments in gene Y, irrespective of their location. This procedure was performed for all pairs of individuals in our sample (*n* = 186). We retained pairs of fragments with a sequence identity \>90%. Within these pairs, a mutation observed at a given position in gene X was declared as being a putative gene conversion event when its derived state (fixed or polymorphic) was equal to the ancestral or derived state observed at the same position in gene Y. However, situations that could be most parsimoniously explained by a single point mutation (i.e., a mutation fixed for the derived state in gene X and fixed for the ancestral allele at the same position in gene Y) were not considered as a conversion event. For each gene, this method provided a set of mutations probably resulting from gene conversion. We declared the putative acceptor and donor genes on the basis of the frequencies of converted mutations (i.e., the donor has the highest frequency of the conversion event).

We evaluated the power of the method to detect gene conversion events and the influence of their removal on the detection of selection by means of coalescence simulations, using SIMCOAL v2 ([@bib44]). We simulated two duplicated genes in the human and chimpanzee lineages, with the gene duplication predating the divergence of the two species. 20 human sequences (10 individuals) and 1 chimpanzee sequence were simulated with the following parameters: the recombination rate expected in humans (1cM/Mb), a human/chimpanzee divergence time of 5 million years, constant population sizes (*n* = 1,000 individuals), and a mutation rate adjusted to the number of mutations observed in our dataset. The two duplicated genes, each 2,000 bp long, were simulated using a global sequence identity between paralogs set to be equal to 90%. In addition, 30% of sites were set to be nonsynonymous, with a sequence identity set to be equal to 95% in coding regions. When gene conversion was introduced, a fixed number of conversion events were simulated using a tract length set at 100 bp (consistent with empirical estimates of mean tract length ([@bib52])). We allowed conversion when sequence identity between tracts was \>60%, specifying that 90% of the conversion events simulated involved a sequence identity \>90%. Next, all mutations present in the tract of the donor gene (both fixed and polymorphic within the human lineage) were copied in the acceptor gene. To evaluate the impact of gene conversion in a more realistic scenario, we also introduced purifying selection on nonsynonymous sites by using a lower mutation rate at nonsynonymous sites with respect to silent sites. We then applied our method of gene conversion detection and calculated the power to detect the gene conversion events and the false discovery rate (Fig. S1).

All variants identified as resulting from gene conversion were not considered in the statistical analyses to detect selection. It should be noted that ignoring the events most parsimoniously explained by a point mutation (i.e., fixed mutations in humans) will have no effect on the detection of selection using analyses based on intraspecies polymorphism, and cannot generate false-positive signals of purifying selection using interspecies tests corrected for gene conversion (Fig. S1). In addition, we verified manually if some of the amino acid--altering polymorphisms detected as resulting from gene conversion could be ambiguously explained by gene conversion or mutation, because the erroneous removal of such sites can create spurious signals of purifying selection. Two events were identified as false positives, in *IFNA10* and *IFNA17*, and the corresponding mutations were thus not excluded from our analyses.

### Statistical analyses.

We used Haploview software ([@bib8]) to obtain and visualize levels of linkage disequilibrium in the various genomic regions. Haplotype reconstruction was performed by the Bayesian method, implemented in Phase (v.2.1.1; [@bib69]). We applied the algorithm five times, using different randomly generated seeds, and checked the consistency of the results across runs. The entire dataset was used for the calculation of sequence-based neutrality statistics, including Tajima's *D*, Fu & Li's *D*\*, Fu & Li's *F*\*, Fay & Wu's *H*, in DnaSP v5.1 ([@bib65]). P-values for the various neutrality tests were estimated from 10^4^ coalescent simulations, performed with SIMCOAL 2.0 ([@bib44]) under a finite-site model and using the recombination rate of the tested region reported in HapMap Phase II ([@bib28]) and the deCODE recombination rate given in the UCSC database (<http://genome.ucsc.edu>; [@bib39]). Each of the 10^4^ coalescent simulations was conditional on the observed sample size and the number of segregating sites observed for each gene. We corrected for the effects of demography on diversity patterns by considering two demographic models based on resequencing data for noncoding regions in a set of populations similar to those studied here ([@bib80]; [@bib45]). The main difference between these two demographic models is that the Laval's model takes intercontinental population migration into account ([@bib45]).

We used the McDonald-Kreitman Poisson random field method ([@bib67]; [@bib9]) to search for the effects of natural selection, taking into account both interspecies divergence and within-species polymorphism. For the detection of recent positive selection events, we used the DIND test, based on the iπ~A~/iπ~D~ ratio, where iπ~A~ and iπ~D~ are the levels of nucleotide diversity associated with the haplotypes carrying the ancestral and the derived alleles, respectively ([@bib7]). This test is based on the rationale that a derived allele under positive selection present at high frequency in the population should display lower levels of nucleotide diversity at linked sites than expected, and therefore higher than expected a iπ~A~/iπ~D~ ratio. Singletons and doubletons were excluded from this analysis. To define statistical significance, the iπ~A~/iπ~D~ values estimated for all IFNs and their receptors were compared against a background distribution obtained by means of 10^4^ simulations of the genomic regions concerned, conditional on the number of segregating sites and the recombination rate of the regions, and integrating the demographic models previously described ([@bib80]; [@bib45]). We also used tests based on levels of extended haplotype homozygosity, such as the iHS ([@bib81]). These tests share a similar rationale: an allele that has a high population frequency and that is associated with an unusually long-range haplotype as compared with genome-wide expectations is likely to have been targeted by recent positive selection. This is explained by the rapid increase in allele frequency of the advantageous allele, meaning that recombination will not have enough time to substantially break down the haplotype on which the selected mutation arose ([@bib54]). We assessed the levels of population differentiation for the entire SNP panel, using the *F*~ST~ statistics derived from the analysis of variance ([@bib24]). We identified SNPs presenting extreme levels of population differentiation, a signature of positive selection ([@bib66]; [@bib54]; [@bib6]) by comparing the observed *F*~ST~ values for individual SNPs in the genes studied here with a genome-wide *F*~ST~ distribution. This was calculated using ∼640,000 SNPs genotyped in the same subset of individuals from the HGDP-CEPH dataset ([@bib50]), with the exception of five individuals who were not genotyped. Because *F*~ST~ values depend on allele frequencies, *F*~ST~ comparisons were confined to SNPs presenting similar allele frequencies (i.e., similar expected heterozygosities). Empirical p-values for each SNP in the 27 genes were estimated as previously described ([@bib7]). As the genome-wide *F*~ST~ distribution of the HGDP-CEPH dataset, used here to represent the neutral distribution, includes loci targeted by positive selection ([@bib60]), the comparison of *F*~ST~ values of IFNs against this distribution represents a highly conservative approach to detecting selection. We defined genes under selection conservatively as those (a) for which significant results were obtained after both demographic corrections or for which results are significant at the genome-wide level, and (b) for which significant results were obtained in at least two tests of selection based on different aspects of the data (e.g., allele frequency spectrum tests and *F*~ST~) in the same population. To test the robustness of our results, and to prevent the detection of false positive signatures of positive selection, we measured the probability, within and between the genes in our dataset, of observing neutral simulations exhibiting "significant" results. Specifically, we calculated the number of simulations that exhibit at least two significant tests among Tajima's *D*, DIND test, and *F*~ST~ for each gene given the observed p-values, and corrected by the number of genes in our dataset (27 genes). The functional impact of all amino acid--altering mutations (benign, possibly damaging, or probably damaging) was predicted with the Polyphen algorithm v2 HumDiv ([@bib1]). This method, which takes into account protein structure and/or sequence conservation information for each gene, has been shown to be the best predictor of the fitness effects of amino acid substitutions ([@bib83]).

### Online supplemental material.

Fig. S1 shows the simulations of our method to detect gene conversion events and the impact of their removal on the detection of selection. Fig. S2 shows the levels of linkage disequilibrium in the genomic region encompassing the three type III IFN genes. Fig. S3 shows the DIND analyses for all genes encoding the IFNs and their receptors in all populations. Table S1 provides details of the resequenced regions for the genes encoding the IFNs and their receptors. Table S2 lists all exonic SNPs detected at the IFN genes and their receptors. Table S3 shows the diversity indices across the genes encoding the IFNs and their receptors. Table S4 lists the number of gene conversion events, including silent and nonsynonymous sites, detected in type I and type III IFN families. Table S5 lists detected gene conversion events, where acceptor genes receive a derived amino acid--altering polymorphism from a putative donor gene. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20111680/DC1>.
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